SPHK1 and breast carcinoma: Despite the landmark success of PARP inhibitors in breast cancer therapy, the molecular mechanisms underlying resistance—particularly the pro-survival signaling mediated by sphingolipid-metabolic enzyme SPHK1—remain insufficiently understood.